Harrow (Nasdaq: HROW) is a U.S.-based pharmaceutical company specializing in ophthalmic treatments. The company is dedicated to enhancing patient access to critical medications while ensuring affordability. Harrow is committed to innovation and the delivery of high-value pharmaceutical solutions, focusing on underserved markets and leveraging real-world clinical experiences to mitigate investment risks. The company's extensive ophthalmic portfolio includes a variety of products addressing conditions like dry eye disease, anterior segment disorders, and more specialized therapeutic needs. With a strong emphasis on ethical practices, Harrow also supports mission work globally by providing free medicines to ophthalmologists working in underserved areas, aiming to preserve and restore the gift of sight to those in need. They prioritize cultivating a collaborative and entrepreneurial company culture, encouraging creativity and commitment among their team members.